The knock on the company is going stale: this quarter's own facts cut against the standing doubt
The model's full reasoning — Q4 2022 call → NO我们根据要求,从转录中识别一个明确的、公司特定的疑虑,以及当前期间的实际运营证据是否明显反驳该疑虑。 首先,寻找疑虑。在电话会议中,管理层多次提到宏观经济逆风,如利率、天然气价格、通货膨胀,但这些都是普遍性的。然而,有一个特定的公司疑虑:关于其增长前景和盈利能力的担忧,特别是由于短期债务和利息支出增加,以及监管滞后。分析师提问中,Julien Dumoulin-Smith 询问了股息支付率和结构性重置,暗示了对未来盈利的担忧。Chris Ellinghaus 询问了供应成本,Andrew Weisel 询问了增长率和监管日历。但最明显的公司特定疑虑是:公司能否维持其增长率和股息?管理层在回应中承认了短期压力,但强调长期战略。然而,是否有“standing doubt”在电话会议之前就存在?管理层提到“我们认识到我们的监管策略将不得不调整”,以及“我们正在解决增加的携带成本和通货膨胀影响”,这表明投资者可能担心公司无法收回成本或增长放缓。但这是否是“standing knock”?可能。 更具体的是,管理层在回答中提到了“我们修订了长期EPS增长目标,主要由于三个因素”,这表明投资者可能担心增长目标下调。但这是否是“standing doubt”?可能。 然而,问题要求一个“well-defined DOUBT”,例如“怀疑其损失永远不会结束”、“其产品没有重复需求”等。这里没有明显的产品问题。公司是公用事业,有稳定的需求。疑虑可能是关于其财务实力或增长能力。 另一个角度:管理层提到“我们正在解决增加的携带成本和通货膨胀影响”,以及“我们预计这些压力将在未来12-18个月内缓解”,但“近期盈利影响超出了可以通过短期财务纪律和成本控制措施完全抵消的范围”。这暗示投资者可能担心公司无法应对这些压力。但这是否是“standing doubt”?可能。 然而,问题要求“standing knock evident from the transcript itself”,即从转录中可以看出一个特定的疑虑。分析师的问题确实集中在增长率和股息上,但管理层没有明确说“投资者担心X”。不过,管理层在回答中承认了“我们修订了长期EPS增长目标”,这暗示了投资者可能担心增长放缓。 但更关键的是,当前期间的实际运营证据是否明显反驳该疑虑?管理层提到了“我们成功抵消了2022年大部分宏观经济快速转变的影响”,但“增加的携带成本正在影响2023和2024年的预期”。这似乎证实了疑虑,而不是反驳。 然而,管理层也提到了“我们继续提供行业领先的电力可靠性”、“客户增长”、“新的峰值负荷”等,这些是积极的运营证据。但疑虑是关于财务增长,而不是运营可靠性。 再仔细看:疑虑可能是“公司能否维持其股息增长?”管理层说“我们预计将继续我们52年的股息增长记录”,但这是预期,不是实际发生。当前期间的实际证据是股息增加了5%,但那是2022年,不是当前期间。 问题要求“THIS PERIOD'S REAL ACTIVITY CUTS AGAINST IT”,即当前期间(2022年第四季度和全年)的实际活动。管理层报告了EPS增长6%,但那是全年,而第四季度持平。此外,管理层承认了短期债务增加和利息支出增加。 也许疑虑是“公司能否收回Winter Storm Uri的成本?”管理层说“我们已批准所有剩余申请,并已收回超过三分之一”,这是实际进展,但那是关于Uri的,不是当前期间。 另一个可能的疑虑:关于可再生能源投资,管理层提到了清洁能源计划,但那是计划,不是实际。 我认为没有明确的“standing doubt”被明确识别。分析师的问题更多是关于指导方针和增长,但管理层没有说“投资者担心X”。然而,管理层在回答中承认了“我们修订了长期EPS增长目标”,这暗示了投资者可能担心增长放缓,但那是公司自己修订的,不是外部疑虑。 也许疑虑是“公司能否维持其信用评级?”管理层提到了“我们致力于维持我们的投资级信用评级”,并提到了评级机构的确认,但那是确认,不是反驳疑虑。 再读转录:在开头,Linn Evans说“我们成功抵消了2022年大部分宏观经济快速转变的影响,但增加的携带成本正在影响我们的预期”,这承认了问题。然后他提到“我们修订了长期EPS增长目标”,这可能是对疑虑的回应。 但问题要求“standing doubt”是“clearly weighing on how this company is perceived”,即一个明显的疑虑。在电话会议中,分析师Julien问“为什么不在2023年调整股息支付率?”这暗示了疑虑。管理层回答“我们相信我们的长期战略”,但那是信心,不是实际证据。 我认为没有足够的证据表明有一个明确的、公司特定的疑虑被反复提及。相反,管理层自己承认了短期压力,但那是事实,不是疑虑。 也许疑虑是“公司能否维持其增长?”管理层提到了“我们预计4%到6%的长期EPS增长”,但那是目标,不是实际。 当前期间的实际证据:EPS增长6%,但那是全年,且部分得益于天气。第四季度持平。此外,短期债务增加。 我认为没有明显的“standing doubt”被识别。因此,答案应为NO。 但让我们再检查:是否有分析师提到“怀疑其损失永远不会结束”?没有。是否有“产品没有重复需求”?没有。是否有“依赖单一客户”?没有。 因此,答案应为NO。
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| CRGO | Freightos Limited | Q1 2024 | 2024-05-20 | C+ |
| IFS | Intercorp Financial Services Inc. | Q1 2024 | 2024-05-14 | C+ |
| PRA | ProAssurance Corporation | Q1 2024 | 2024-05-11 | D |
| LTRX | Lantronix, Inc. | Q3 2024 | 2024-04-29 | C |
| ASB | Associated Banc-Corp | Q1 2024 | 2024-04-25 | A |
| GL | Globe Life Inc. | Q1 2024 | 2024-04-23 | F |
| ASM | Avino Silver & Gold Mines Ltd. | Q4 2023 | 2024-03-21 | C+ |
| KOPN | Kopin Corporation | Q4 2023 | 2024-03-14 | C+ |
| GIII | G-III Apparel Group, Ltd. | Q4 2024 | 2024-03-14 | C |
| HP | Helmerich & Payne, Inc. | Q1 2024 | 2024-01-30 | C |
| PFE | Pfizer Inc. | Q4 2023 | 2024-01-30 | F |
| QTRX | Quanterix Corporation | Q3 2023 | 2023-11-07 | B |
| ALL | The Allstate Corporation | Q3 2023 | 2023-11-02 | C+ |
| DASH | DoorDash, Inc. | Q3 2023 | 2023-11-01 | C+ |
| PTN | Palatin Technologies, Inc. | Q4 2023 | 2023-09-29 | D |
| BZUN | Baozun Inc. | Q2 2023 | 2023-08-28 | D |
| GVP | GSE Systems, Inc. | Q1 2023 | 2023-05-15 | D |
| BXSL | Blackstone Secured Lending Fund | Q1 2023 | 2023-05-10 | A |
| FTHM | Fathom Holdings, Inc. | Q1 2023 | 2023-05-10 | C |
| SPIR | Spire Global, Inc. | Q1 2023 | 2023-05-10 | B |
| SBRA | Sabra Health Care REIT, Inc. | Q1 2023 | 2023-05-04 | B |
| BRX | Brixmor Property Group Inc. | Q1 2023 | 2023-05-02 | A |
| TACT | TransAct Technologies Incorporated | Q4 2022 | 2023-03-08 | A |
| VRE | Veris Residential, Inc. | Q4 2022 | 2023-02-22 | D |
| TOST | Toast, Inc. | Q4 2022 | 2023-02-16 | C+ |
| PKOH | Park-Ohio Holdings Corp. | Q3 2022 | 2022-11-13 | B |
| CLSD | Clearside Biomedical, Inc. | Q3 2022 | 2022-11-09 | C |
| SIBN | SI-BONE, Inc. | Q3 2022 | 2022-11-07 | C+ |
| CHE | Chemed Corporation | Q3 2022 | 2022-11-01 | B+ |
| YMM | Full Truck Alliance Co. Ltd. | Q2 2022 | 2022-08-25 | C+ |
| EXFY | Expensify, Inc. | Q2 2022 | 2022-08-12 | D |
| WD | Walker & Dunlop, Inc. | Q2 2022 | 2022-08-09 | C+ |
| DM | Desktop Metal, Inc. | Q2 2022 | 2022-08-08 | F |
| XHR | Xenia Hotels & Resorts, Inc. | Q2 2022 | 2022-08-05 | A |
| LIN | Linde plc | Q2 2022 | 2022-07-28 | B+ |
| CME | CME Group Inc. | Q2 2022 | 2022-07-27 | B |
| OGI | OrganiGram Holdings Inc. | Q3 2022 | 2022-07-14 | B+ |
| SE | Sea Limited | Q1 2022 | 2022-05-17 | F |
| VNRX | VolitionRx Limited | Q1 2022 | 2022-05-12 | F |
| OPK | OPKO Health, Inc. | Q1 2022 | 2022-05-09 | D |
| FARM | Farmer Bros. Co. | Q3 2022 | 2022-05-07 | D |
| BFIN | BankFinancial Corporation | Q1 2022 | 2022-05-06 | A |
| BXP | Boston Properties, Inc. | Q1 2022 | 2022-05-03 | A |
| STC | Stewart Information Services Corporation | Q1 2022 | 2022-04-29 | C+ |
| LOW | Lowe's Companies, Inc. | Q3 2021 | 2021-11-17 | B+ |
| CYBR | CyberArk Software Ltd. | Q3 2021 | 2021-11-04 | B+ |
| IPGP | IPG Photonics Corporation | Q3 2021 | 2021-11-02 | C |
| SXC | SunCoke Energy, Inc. | Q3 2021 | 2021-11-01 | A |
| EMR | Emerson Electric Co. | Q3 2021 | 2021-08-04 | B+ |
| EEX | Emerald Holding, Inc. | Q2 2021 | 2021-08-01 | C+ |
| GECC | Great Elm Capital Corporation | Q3 2018 | 2018-11-13 | B |
| UMH | UMH Properties, Inc. | Q3 2018 | 2018-11-02 | C+ |
| FOSL | Fossil Group, Inc. | Q1 2018 | 2018-05-08 | C |
| BCOV | Brightcove Inc. | Q1 2018 | 2018-04-26 | B+ |
| AVT | Avnet, Inc. | Q2 2018 | 2018-01-25 | B |
| PII | Polaris Inc. | Q3 2017 | 2017-10-24 | C+ |
| GNTX | Gentex Corporation | Q3 2017 | 2017-10-20 | B |
| MTG | MGIC Investment Corporation | Q3 2017 | 2017-10-18 | B+ |
| LIND | Lindblad Expeditions Holdings, Inc. | Q2 2017 | 2017-08-06 | C |
| BIIB | Biogen Inc. | Q2 2017 | 2017-07-25 | B |
| CAG | Conagra Brands, Inc. | Q2 2017 | 2016-12-22 | C+ |
| WYY | WidePoint Corporation | Q3 2016 | 2016-11-09 | D |
| ULBI | Ultralife Corporation | Q3 2016 | 2016-10-29 | C+ |
| ARAY | Accuray Incorporated | Q4 2016 | 2016-08-17 | B |
| GES | Guess?, Inc. | Q1 2017 | 2016-05-25 | F |
| RCL | Royal Caribbean Cruises Ltd. | Q1 2016 | 2016-04-29 | C+ |
| DD | DuPont de Nemours, Inc. | Q1 2016 | 2016-04-26 | B+ |
| HPP | Hudson Pacific Properties, Inc. | Q4 2015 | 2016-02-25 | C |
BRX · Q1 2023 → YESThe question asks if there's a standing company-specific doubt visible on the call, and if this period's operating evidence cuts against it. YES The standing doubt is the skepticism that tenant disruptions (especially bankruptcies like Bed Bath) will create occupancy pressure and throw markets out of equilibrium, given the recaptured space and potential for more filings. This is visible in analyst questions (Todd Thomas on Bed Bath impact and market equilibrium; others circling back on bad debt 75-110 bps and bankruptcy activity) and management's acknowledgment that "recent retailer bankruptcy announcements will result in occupancy pressure" while noting they've "been preparing for the last several quarters." This period's evidence cuts against it: record 94% total occupancy (up sequentially in a seasonally weak quarter), small-shop at 89.
CME · Q2 2022 → YESThe question is: Identify ONE well-defined DOUBT that has been weighing on the company, and see if the current period's operating evidence moves against that doubt. YES The standing doubt is the perceived risk that the legacy NEX Group businesses (BrokerTec and EBS) would continue to show range-bound revenue and fail to deliver meaningful growth despite a constructive macro backdrop, as directly raised by Alex Blostein. Management engages this concern head-on by recounting concrete operating evidence from 2Q: BrokerTec US treasuries ADV up 14% YoY, US repo up 25% YoY, EU repo up 14% YoY, plus $4.5 billion in new cross-sell volume from previously non-trading clients and record RV trading volumes of $2.4 billion; 90% of the migration to Globex is complete, with the remaining EBS migration also finished and system enhancements underway.
BXSL · Q1 2023 → YESThe question asks if there's a standing company-specific doubt visible in the transcript, and if this period's operating evidence moves against it. YES The standing doubt visible in the transcript is the skepticism that BXSL’s credit performance will be materially worse than the broader private-credit market because of its exposure to higher-rate environments and the “tails” of the portfolio (i.e., the small slice of companies whose interest-coverage ratios could fall below 1× when 5 % rates are stress-tested). Management itself flags this concern by noting that “it is less about averages… much more about the tails” and that investors keep asking about the percentage of the portfolio below 1× ICR. This quarter’s operating evidence directly counters that doubt: - 0.